See more : Anchorstone Holdings Limited (1592.HK) Income Statement Analysis – Financial Results
Complete financial analysis of HUTCHMED (China) Limited (HCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HUTCHMED (China) Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Northland Power Inc (NPIWF) Income Statement Analysis – Financial Results
- GreenX Metals Limited (GRX.AX) Income Statement Analysis – Financial Results
- Viridian Therapeutics, Inc. (VRDN) Income Statement Analysis – Financial Results
- Esken Limited (ESKNF) Income Statement Analysis – Financial Results
- Zhuhai Winbase International Chemical Tank Terminal Co.,Ltd (002492.SZ) Income Statement Analysis – Financial Results
HUTCHMED (China) Limited (HCM)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.hutch-med.com
About HUTCHMED (China) Limited
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 838.00M | 426.41M | 356.13M | 227.98M | 204.89M | 214.11M | 241.20M | 216.08M | 178.20M | 91.81M | 45.97M | 195.39M | 166.92M | 134.51M | 111.00M | 86.97M | 65.11M | 50.43M | 37.86M |
| Cost of Revenue | 384.45M | 311.10M | 258.23M | 188.52M | 160.15M | 143.94M | 175.82M | 156.33M | 110.78M | 72.05M | 22.21M | 99.40M | 74.16M | 54.64M | 44.59M | 36.13M | 27.66M | 21.32M | 14.62M |
| Gross Profit | 453.55M | 115.31M | 97.89M | 39.46M | 44.74M | 70.17M | 65.38M | 59.75M | 67.43M | 19.76M | 23.76M | 95.99M | 92.77M | 79.87M | 66.41M | 50.84M | 37.45M | 29.11M | 23.24M |
| Gross Profit Ratio | 54.12% | 27.04% | 27.49% | 17.31% | 21.84% | 32.77% | 27.11% | 27.65% | 37.84% | 21.53% | 51.69% | 49.13% | 55.57% | 59.38% | 59.83% | 58.46% | 57.52% | 57.72% | 61.40% |
| Research & Development | 303.06M | 267.59M | 207.45M | 111.23M | 91.94M | 78.82M | 50.68M | 66.87M | 47.37M | 33.47M | 23.44M | 5.89M | 7.29M | 6.41M | 3.86M | 8.81M | 5.64M | 2.77M | 2.05M |
| General & Administrative | 79.78M | 92.17M | 89.30M | 50.02M | 39.21M | 30.91M | 23.96M | 21.58M | 19.62M | 22.57M | 21.30M | 35.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 53.39M | 43.93M | 37.83M | 11.33M | 13.72M | 17.74M | 19.32M | 18.00M | 10.21M | 4.11M | 3.45M | 62.68M | 56.50M | 52.70M | 44.81M | 31.74M | 23.09M | 16.04M | 18.20M |
| SG&A | 133.18M | 136.11M | 127.13M | 61.35M | 52.93M | 48.65M | 43.28M | 39.58M | 29.83M | 26.68M | 24.75M | 98.41M | 56.50M | 52.70M | 44.81M | 31.74M | 23.09M | 16.04M | 18.20M |
| Other Expenses | 0.00 | 119.31M | 91.64M | 63.54M | 44.88M | -781.00K | 116.00K | 609.00K | 184.00K | 261.00K | 65.00K | -1.01M | 23.39M | -225.46K | -282.96K | -1.22M | -937.60K | -557.58K | -175.47K |
| Operating Expenses | 436.23M | 523.00M | 426.21M | 236.13M | 189.76M | 161.01M | 118.80M | 106.59M | 77.20M | 26.87M | 23.14M | 95.36M | 87.18M | 82.46M | 71.51M | 64.98M | 47.36M | 34.50M | 29.16M |
| Cost & Expenses | 819.62M | 834.10M | 684.45M | 424.64M | 349.91M | 304.95M | 294.62M | 262.92M | 187.97M | 98.92M | 45.35M | 194.76M | 161.34M | 137.10M | 116.10M | 101.11M | 75.01M | 55.82M | 43.77M |
| Interest Income | 36.15M | 9.60M | 2.08M | 3.24M | 4.94M | 5.98M | 1.22M | 502.00K | 451.00K | 559.00K | 451.00K | 578.00K | 133.65K | 225.46K | 282.96K | 1.22M | 937.60K | 559.54K | 175.47K |
| Interest Expense | 759.00K | 652.00K | 592.00K | 787.00K | 1.03M | 1.01M | 1.46M | 1.63M | 1.40M | 1.05M | 1.01M | 737.00K | 561.03K | 402.38K | 399.37K | 527.87K | 299.15K | 388.73K | 495.45K |
| Depreciation & Amortization | 8.21M | 8.66M | 7.19M | 6.06M | 4.94M | 3.59M | 2.58M | 2.30M | 2.02M | 1.27M | 963.00K | 4.05M | 4.56M | 4.58M | 4.57M | 4.65M | 3.80M | 2.87M | 2.32M |
| EBITDA | 25.53M | -401.11M | -207.96M | -182.89M | -135.13M | -82.06M | -49.50M | -43.39M | -7.16M | -17.17M | 1.58M | -6.79M | 10.20M | 2.37M | -46.89K | -9.58M | -5.92M | -2.51M | -3.42M |
| EBITDA Ratio | 3.05% | -94.07% | -92.46% | -80.22% | -65.95% | -38.32% | -20.52% | -20.08% | -4.00% | -6.36% | 3.44% | -3.48% | 6.11% | 2.01% | 0.13% | -10.88% | -8.61% | -4.83% | -9.51% |
| Operating Income | 18.38M | -409.77M | -336.46M | -188.95M | -145.02M | -92.64M | -53.42M | -46.70M | -9.77M | 8.10M | 11.56M | 12.11M | 5.39M | -2.21M | -4.61M | -14.23M | -9.72M | -5.38M | -5.73M |
| Operating Income Ratio | 2.19% | -96.10% | -94.48% | -82.88% | -70.78% | -43.27% | -22.15% | -21.61% | -5.48% | 8.82% | 25.14% | 6.20% | 3.23% | -1.64% | -4.16% | -16.36% | -14.93% | -10.67% | -15.13% |
| Total Other Income/Expenses | 39.93M | -2.73M | 112.58M | 6.93M | 5.28M | 5.99M | -119.00K | -659.00K | -767.49K | 13.48M | 28.99M | -17.37M | -1.96M | -402.38K | -399.37K | -527.87K | -299.15K | -386.77K | -502.33K |
| Income Before Tax | 58.31M | -410.42M | -215.74M | -189.73M | -141.11M | -86.66M | -53.54M | -47.36M | -10.54M | 6.58M | 10.07M | 10.90M | 4.83M | -2.61M | -5.01M | -14.76M | -10.02M | -5.77M | -6.23M |
| Income Before Tax Ratio | 6.96% | -96.25% | -60.58% | -83.23% | -68.87% | -40.47% | -22.20% | -21.92% | -5.91% | 7.17% | 21.91% | 5.58% | 2.89% | -1.94% | -4.52% | -16.97% | -15.39% | -11.44% | -16.46% |
| Income Tax Expense | 4.51M | -283.00K | 11.92M | 4.83M | 3.27M | 3.96M | 3.08M | 4.33M | 1.61M | 1.34M | 1.05M | 4.16M | 3.14M | 2.58M | 2.07M | 1.50M | 837.21K | 1.96K | 141.06K |
| Net Income | 100.78M | -410.14M | -227.66M | -194.56M | -144.38M | -74.81M | -26.74M | 11.70M | 7.99M | 5.37M | 5.92M | 3.64M | 710.22K | -6.86M | -8.75M | -17.76M | -17.19M | -9.61M | -6.78M |
| Net Income Ratio | 12.03% | -96.18% | -63.93% | -85.34% | -70.47% | -34.94% | -11.08% | 5.41% | 4.49% | 5.85% | 12.87% | 1.86% | 0.43% | -5.10% | -7.88% | -20.41% | -26.40% | -19.05% | -17.90% |
| EPS | 0.59 | -0.48 | -0.29 | -0.28 | -0.22 | -0.11 | -0.04 | 0.10 | -0.32 | 0.05 | 0.06 | 0.04 | 0.01 | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 |
| EPS Diluted | 0.58 | -0.48 | -0.29 | -0.28 | -0.22 | -0.11 | -0.04 | 0.10 | -0.32 | 0.05 | 0.06 | 0.03 | 0.01 | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 |
| Weighted Avg Shares Out | 169.93M | 847.14M | 792.68M | 697.93M | 665.68M | 664.26M | 617.17M | 597.15M | 546.59M | 525.63M | 520.51M | 519.19M | 517.43M | 515.28M | 512.32M | 512.29M | 512.16M | 457.13M | 366.67M |
| Weighted Avg Shares Out (Dil) | 173.84M | 847.14M | 792.68M | 697.93M | 665.68M | 664.26M | 617.17M | 599.71M | 546.59M | 528.94M | 528.78M | 526.50M | 526.54M | 515.28M | 512.32M | 512.29M | 512.16M | 457.13M | 366.67M |
Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
Source: https://incomestatements.info
Category: Stock Reports